GI-5005: Preliminary Phase IIb data

Preliminary data from an open-label Phase IIb trial in 27 patients with the T/T genotype of interleukin-28B (IL-28B; IFNL3) showed that GI-5005 plus pegylated interferon and ribavirin produced a 63% ...